

Remarks

Currently Claims 1-32 and 43-45 are pending. Claims 33-42 are canceled.

Claims 4, 5, 7-19, 21, 24-25, 27-30 and 32 are amended herein to remove multiple dependencies for the purpose of reducing claim fees. The amendments do not narrow the scope of the claims and are not being made for reasons of patentability. No new matter is added.


New claims 43-45 are added. Support for these claims can be found throughout Applicants specification, including at page 26, lines 1-9, page 30, lines 15-17 and Examples 126, 127 and 157. No new matter is added.

The specification has been amended to recite related applications and to provide an abstract on a separate page. No new matter is added.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 31 January, 2005
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
Lorie.A.Morgan@gsk.com